As the introduction of anti-HER2-treatment significantly improved the prognosis of HER2-positive breast cancer patients, we hypothesize that the worse survival described in previous studies might have been associated with HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.